Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Gynecol Oncol. 2017 Oct 14;147(3):521–527. doi: 10.1016/j.ygyno.2017.09.034

Table 2.

Stage, level of differentiation, treatment and outcome for 49 individuals with SLCT.

Stage Differentiation Adjuvant Chemo Surgery Only NED Metachronous Relapse DOD

IA Well (n=2) 0 2 2 0 0 0
[T1aN0M0] (n=27) Intermediate (n=20) 3 17 20 2 0 0
Poor (n=4) 3 1 4 1 0 0
Unknown (n=1) 1 0 1 0 0 0

IC [T1cN0M0] (n=6) Intermediate (n=1) 0 1 0 0 1 1
Poor (n=5) 2 3 2 0 3 1

IC1 [T1C1N0M0] (n=6) Intermediate (n=2) 2 0 2 0 0 0
Poor (n=3) 1 2 2 0 1 1
Unknown (n=1) 1 0 1 0 0 0

>IC [T1cN0M0] (n=4) Intermediate (n=2) 2 0 2 0 0 0
Poor (n=2) 2 0 0 0 1 0

Unknown (n=6) Well (n=1) 0 1 1 0 0 0
Intermediate (n=1) 0 1 1 0 0 0
Unknown (n=4) 1 3 2 0 2 1

All stages (n=49) Well (n=3) 0 3 3 0 0 0
Intermediate (n=26) 7 19 25 2 1 1
Poor (n=14) 8 6 8 1 5 2
Unknown (n=6) 3 3 4 0 2 1

FIGO 1a: limited to one ovary, capsule intact, negative washings; 1c1: surgical spill. SLCT= Sertoli-Leydig cell tumor, NED= no evidence of disease, DOD= died of disease, Chemo= chemotherapy, NOS= not otherwise specified